{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-014808","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2024-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.820013+00:00","generated_at":"2026-06-06T18:28:51.402613+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vera Therapeutics reports positive 72-week Phase 2b atacicept data with eGFR stabilization in IgAN","bullets":["Atacicept 150mg for 72 weeks: 62% reduction in Gd-IgA1, hematuria to 19%, 48% reduction in UPCR (PP analysis).","eGFR stable with 0 mL/min/1.73m² change from baseline; placebo-to-atacicept switchers halted eGFR decline (-3.2 vs -4.9 at 36wks).","Safety consistent with prior trials; generally well-tolerated in OLE.","Phase 3 ORIGIN 3 enrollment on track for H2 2024; topline data expected H1 2025; BLA submission planned H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-014808","json":"https://secwatch.observer/filing/0001193125-24-014808.json","markdown":"https://secwatch.observer/filing/0001193125-24-014808.md","text":"https://secwatch.observer/filing/0001193125-24-014808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312524014808/0001193125-24-014808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312524014808/d717089d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T18:28:51.402613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}